Last reviewed · How we verify
Arterakin (DHA-PPQ)
Arterakin (DHA-PPQ) is a Artemisinin-based combination therapy (ACT) Small molecule drug developed by National Institute of Malariology, Parasitology and Entomology, Vietnam. It is currently FDA-approved for Uncomplicated malaria caused by Plasmodium falciparum, Uncomplicated malaria caused by Plasmodium vivax.
Arterakin combines dihydroartemisinin (DHA) and piperaquine (PPQ) to kill malaria parasites by generating reactive oxygen species and disrupting parasite hemoglobin digestion.
Arterakin (DHA-PPQ) is a small molecule intervention studied for its efficacy against Plasmodium Falciparum. It was investigated in the "Plasmodium Falciparum Artemisinin Resistance Vietnam" clinical trial, which monitored its effectiveness in patients with uncomplicated falciparum malaria.
At a glance
| Generic name | Arterakin (DHA-PPQ) |
|---|---|
| Sponsor | National Institute of Malariology, Parasitology and Entomology, Vietnam |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Plasmodium falciparum heme; parasite food vacuole |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Dihydroartemisinin is an artemisinin derivative that generates free radicals upon interaction with parasite heme, causing oxidative damage to Plasmodium parasites. Piperaquine is a quinoline-type antimalarial that accumulates in the parasite's food vacuole and inhibits hemoglobin digestion. The combination provides synergistic antimalarial activity with a lower risk of resistance development compared to monotherapy.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Uncomplicated malaria caused by Plasmodium vivax
Common side effects
- Headache
- Dizziness
- Nausea
- Abdominal pain
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arterakin (DHA-PPQ) CI brief — competitive landscape report
- Arterakin (DHA-PPQ) updates RSS · CI watch RSS
- National Institute of Malariology, Parasitology and Entomology, Vietnam portfolio CI
Frequently asked questions about Arterakin (DHA-PPQ)
What is Arterakin (DHA-PPQ)?
How does Arterakin (DHA-PPQ) work?
What is Arterakin (DHA-PPQ) used for?
Who makes Arterakin (DHA-PPQ)?
What drug class is Arterakin (DHA-PPQ) in?
What development phase is Arterakin (DHA-PPQ) in?
What are the side effects of Arterakin (DHA-PPQ)?
What does Arterakin (DHA-PPQ) target?
Related
- Drug class: All Artemisinin-based combination therapy (ACT) drugs
- Target: All drugs targeting Plasmodium falciparum heme; parasite food vacuole
- Manufacturer: National Institute of Malariology, Parasitology and Entomology, Vietnam — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Uncomplicated malaria caused by Plasmodium falciparum
- Indication: Drugs for Uncomplicated malaria caused by Plasmodium vivax
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing